Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. reports developments as a clinical-stage biotechnology company focused on intravitreal gene therapy for ocular diseases. Its updates center on ixoberogene soroparvovec, or Ixo-vec, a one-time intravitreal candidate for neovascular, or wet, age-related macular degeneration, including ARTEMIS Phase 3 trial communications and clinical or regulatory disclosures.
Recurring news also includes operating and financial results, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), material agreements, capital-structure matters, shareholder and governance disclosures, and corporate transaction communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.